Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-1: Durvalumab and Bevacizumab with TACE in Hepatocellular Carcinoma
NCT03778957Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Primary completion
- Sep 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of durvalumab and bevacizumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression Free Survival for Arm B vs Arm C at 5 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
durvalumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03778957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778957.